Audience: Veterinary World readers represent education, industry and government, including research, teaching, administration, veterinary medicine and technical services in more than 150 countries. Veterinary World is of interest to those in veterinary medicine, infectious diseases, public health, parasitology, food science, epidemiology, immunology, virology, bacteriology, nutrition, pathology, physiology, gynaecology, wildlife.
Wednesday, 11 October 2017
Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus
Research (Published online: 11-10-2017)
9. Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus
Zeinab Mohamed Ali, Mervat Abd El Monaem Hassan, Hussein Ali Hussein, Basem Mohamed Ahmed and Ahmed Abd El-Ghany El Sanousi
Veterinary World, 10(10): 1212-1220
Aim: The objective of the present study was to prepare a trivalent inactivated vaccine of Newcastle disease virus (NDV), H5N1, and H9N2 viruses.
Materials and Methods: Three monovalent and a trivalent vaccines were prepared by emulsifying inactivated NDV (LaSota strain), reassortant H5N1, and H9N2 viruses with Montanide ISA 71 oil adjuvant. Parameters used for evaluation of the efficacy of the prepared vaccines in specific pathogen-free chickens were cellular immunity assays (blastogenesis, interferon gamma, interleukin 1 [IL1], and IL6), humoral immunity by hemagglutination inhibition, protection percentage, and shedding.
Results: A single immunization with trivalent vaccine-enhanced cell-mediated immunity as well as humoral immune response with 90% protection against challenges with highly pathogenic avian influenza (HPAI) H5N1 and low pathogenic (LP) avian influenza H9N2 viruses with 100% protection after challenge with NDV.
Conclusion: Development and evaluation of the trivalent vaccine in the study reported the success in preparation of a potent and efficacious trivalent vaccine which is a promising approach for controlling HPAI H5N1, LP H9N2, and ND viral infections.